Metadata supporting data files in the published article: Folate Receptor Alpha Expression Associates with Improved Disease Free Survival in Triple Negative Breast Cancer Patients
Creators: name: Norton, Nadine
name: Bahaaeldin Youssef
name: Hillman, David W.
name: Nassar, Aziza
name: Xochiquetzal J. Geiger
name: Necela, Brian M.
name: Heshan Liu
name: Ruddy, Kathryn J.
name: Polley, Mei-Yin C.
name: Ingle, James N.
name: Couch, Fergus J.
name: Perez, Edith A.
name: Minetta C. Liu
name: Carter, Jodi M.
name: Leon-Ferre, Roberto A.
name: Boughey, Judy C.
name: Somers, Elizabeth B.
name: Kalari, Krishna R.
name: Visscher, Daniel W.
name: Goetz, Matthew P.
name: Knutson, Keith L.
Publisher: name: figshare
Year: 2020
Subjects: subject: Cancer
subject: Medicine
subject: 111203 Cancer Genetics
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: Biological Techniques
subject: Biomarkers

description: In this study, the authors optimized and validated a folate receptor alpha (FRα) immunohistochemistry method, specific to triple negative breast cancer (TNBC), to measure FRα expression in a centrally confirmed cohort of 384 patients with TNBC in order to determine if expression of the protein is associated with invasive disease free survival (IDFS) and overall survival (OS).<br><b>Data access</b>: The 6 .tif files (Image_A for folate receptor.tif, Image_B for folate receptor.tif, Image_C for folate receptor.tif, Image_D for folate receptor.tif, Image_E for folate receptor.tif and Image_F for folate receptor.tif) make up figure 1 of the published article. Data supporting figures 2 and 3 and tables 1-3 are not publicly available in order to protect patient privacy, but can be made available on request from the corresponding author. The corresponding author will evaluate whether the completion of a Data Usage Agreement is required. Corresponding author details are: Dr. Nadine Norton, Department of Cancer Biology, Mayo Clinic Jacksonville, email: <b>norton.nadine@mayo.edu</b>. The data supporting supplementary figures 1-6 are available as a supplementary file with the name Supplementary Data.docx (.xlsx data are embedded within the .docx file).<br><b>Study approval and patient consent</b>: All breast cancer specimens were collected according to a protocol that was approved by the Mayo Clinic Institutional Review Board (IRB). The study was conducted in accordance with the U.S. Common rule with written, informed consent being obtained from each participating patient.<br><b>Study aims and methodology</b>: The aim of this study was to evaluate the association of FRα protein expression with IDFS and OS, using a rigorously tested immunostaining protocol in a large, well-annotated cohort of 384 centrally reviewed TNBC patients.A tissue microarray (TMA) was constructed for the purpose of antibody optimization consisting of 1 mm core punches from deidentified waste tissue: 8 from liver and 8 from spleen, intended as negative controls; 3 replicate punches of each of 19 TNBC breast tumors; 3 replicate punches of each of 6 normal breast tissues and 3 replicate punches of each of 6 serous ovarian cancer, tissues intended as positive controls. Samples from this TMA and 5 μm sections from the same patients were used to optimize and test antibody dilution, intra- and inter-assay variability, reproducibility between different antibody lots and antigen stability.Immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded (FFPE) tissue microarrays using a MACH4 Universal HRP-Polymer Detection Kit.For immunohistochemistry scoring, digital images of the stained TMA slides were obtained using an Aperio ScanScope Image Scanner (Aperio Technologies, Vista, CA). TMAs were evaluated using a semi-quantitative scoring method. A pathologist (BY) scored membrane staining as negative (0), weak (1+), moderate (2+) and strong (3+) membrane staining.For more details on the methodology and statistical analysis, please refer to the published article.<br><b>Data supporting the figures and tables in the published article:</b> Data supporting figure 1: Image files <b>Image_A for folate receptor.tif</b>, <b>Image_B for folate receptor.tif</b>, <b>Image_C for folate receptor.tif</b>, <b>Image_D for folate receptor.tif</b>, <b>Image_E for folate receptor.tif</b> and <b>Image_F for folate receptor.tif </b>are in <b>.tif </b>file format and support figures 1a, 1b, 1c, 1d, 1e and 1f respectively. The .tif files show representative FRα staining of triple negative breast tumors.<br>Data supporting figures 2 and 3: Dataset <b>hscores_with_outcomes.csv</b> is in <b>.csv</b> file format. The dataset includes FRα H-scores, as well as data on invasive disease free survival and overall survival data.<br>Data supporting tables 1, 2 and 3: Dataset <b>ernegfolate.sas </b>is in <b>.sas</b> file format. The dataset includes patient and tumour characteristics, FRα H-scores and data on invasive disease free survival (IDFS) and overall survival.<br><b>Software needed to access data</b>: The SAS software is required to access the .sas files.<br><br>